Escalating conflict in Iran is causing significant price increases and supply disruptions for essential medications in the UK, including life-saving cancer drugs. Experts warn of potential shortages affecting millions of Britons, exacerbating existing NHS challenges.

Impact on UK Healthcare

The crisis isn’t limited to oncology; drugs managing symptoms and side effects of cancer, as well as essential medications for conditions like high blood pressure, pain management, and steroid treatments, are all facing supply disruptions. This builds upon existing challenges within the National Health Service (NHS), which was already grappling with medication shortages.

Disrupted Supply Chains

The conflict has further complicated matters by disrupting vital air freight routes and driving up fuel and shipping costs. This creates a challenging environment for pharmaceutical supply chains. A recent survey by the National Pharmacy Association (NPA), encompassing 400 pharmacies, revealed that all respondents have experienced price increases in commonly prescribed medicines.

Soaring Drug Prices

Some drugs have seen their prices surge by as much as eleven-fold since February, placing immense strain on the NHS budget and the financial viability of pharmacies. Pharmacies are reporting receiving significantly reduced volumes of medication – as little as a quarter of their usual supply – directly attributable to the war-induced price hikes.

Pharmacy Financial Strain

Price concessions from the Department of Health and Social Care (DHSC) have reached their highest levels in years, but many pharmacies are still operating at a loss, as reimbursement rates often fall short of acquisition costs. Olivier Picard, chairman of the NPA, warned of further disruptions if the conflict persists, emphasizing that medicine shortages were already a growing concern.

Specific Drug Shortages

Specific cancer treatments are already experiencing shortages. Medications like Creon (pancreatic cancer) and Efudix (topical chemotherapy) are becoming increasingly scarce. Intravenous cancer drugs such as Endoxan, Sendoxan, and Genoxal – used in the treatment of breast, lung, ovarian cancer, lymphoma, leukaemia, and myeloma – are also in short supply.

Beyond Cancer Care

Medications like Oxybutynin, used to manage hot flushes during hormone therapy, are largely out of stock and have seen price increases exceeding threefold since the start of the year. This widespread disruption underscores the fragility of the pharmaceutical supply chain.

Raw Material Concerns

Mark Samuels, chief executive of Medicines UK, highlighted the impact on raw material supplies. Many critical ingredients rely on petrochemicals sourced through the Strait of Hormuz, which is now facing disruption. Rising fossil fuel costs are also contributing to increased manufacturing expenses.

Generic Medication Vulnerability

The majority of treatments used by NHS patients are off-patent generic medications, which are sold at very low prices, making them particularly susceptible to cost increases. Samuels predicts shortages and price rises in the coming weeks, directly impacting patients across the NHS.

This crisis follows recent warnings regarding supply issues affecting everyday medications, such as Ramipril, a common high blood pressure drug. A ‘serious shortage protocol’ has already been issued for a specific dosage of Ramipril, indicating the severity of the situation.